Clawback and rebate hampering introduction of innovative drugs

Tax collection measures such as the rebate and clawback systems that prevent excessive state spending on pharmaceuticals are hindering the penetration of the Greek market by innovative drugs, says Bruno Wohlschlegel, head of Europe at the Merck Group.

In an interview with Kathimerini, he also noted that an efficient pricing system needs to be introduced, adding that he hopes the Greek state will understand that innovation operates for the benefit of patients.

For the German company, Greece continues to constitute one of the biggest markets in Europe based also on its population, but Wohlschlegel stressed the need for Greek patients to have access to innovative medicines for the treatment of serious diseases such as cancer and multiple sclerosis.

"We are waiting to see the [Greek government's] decisions" on how it will bring the innovative drugs into the market,...